生物瓣膜置换术后前3个月内直接口服抗凝药与维生素K拮抗剂的比较:系统综述与荟萃分析
该系统综述与荟萃分析纳入4项随机对照试验共2284例患者,比较生物瓣膜植入后90天内直接口服抗凝药(DOACs)与维生素K拮抗剂(VKAs)的效果。中位随访12个月,DOACs与VKAs在血栓形成、出血、死亡或亚临床瓣膜血栓方面无统计学显著差异,但瓣膜植入7天内启动DOACs的亚组有出血增多趋势。
要点
- 生物瓣膜植入后90天内,DOACs与VKAs在血栓形成、出血、死亡方面无统计学显著差异。
- 瓣膜植入7天内启动DOACs的亚组有出血增多趋势。
- 证据确定性受事件数少和置信区间宽限制。
核心结论
- 在现有关于生物瓣膜植入后前90天内DOACs与VKAs比较的随机文献中,血栓形成、出血或死亡方面似乎无差异。
- 数据解读受事件数少和置信区间宽的限制。
- 未来研究应聚焦外科瓣膜并纳入长期随访以评估随机治疗对瓣膜耐久性的潜在影响。
研究设计与样本
- 系统综述与荟萃分析,纳入4项随机对照试验共2284例患者,中位随访12个月。
- 2项研究检查经导管瓣膜(1877/2284=83%),2项检查外科瓣膜(407/2284=17%)。
- 系统检索Embase、Medline和CENTRAL,双人筛选、提取数据并评估偏倚风险,采用Mantel-Haenszel法和随机效应模型合并数据。
- 基于瓣膜类型(经导管 vs 外科)和抗凝启动时机(瓣膜植入后<7天 vs >7天)进行亚组分析,采用GRADE方法评估证据确定性。
主要发现
- DOACs与VKAs在血栓形成、出血、死亡或亚临床瓣膜血栓方面无统计学显著差异。
- 瓣膜植入7天内启动DOACs的亚组有出血增多趋势。
临床怎么用
- 原文未据此给出推荐。
局限性
- 数据解读受事件数少和置信区间宽的限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We conducted a systematic review and meta-analysis of randomized controlled trials comparing direct oral anticoagulants (DOACs) to vitamin K antagonists (VKAs) in the first 90 days after bioprosthetic valve implantation. METHODS: We systematically searched Embase, Medline and CENTRAL. We screened titles, abstracts and full texts, extracted data and assessed the risk of bias in duplicate. We pooled data using the Mantel-Haenzel method and random effects modelling. We conducted subgroup analyses based on the type of valve (transcatheter versus surgical) and timing of initiation of anticoagulation (<7 vs >7 days after valve implantation). We assessed the certainty of evidence using the Grading of Recommendations, Assessments, Development and Evaluation approach. RESULTS: We included 4 studies of 2284 patients with a median follow-up of 12 months. Two studies examined transcatheter valves (1877/2284 = 83%) and 2 examined surgical valves (407/2284 = 17%). We found no statistically significant differences between DOACs and VKAs with regard to thrombosis, bleeding, death or subclinical valve thrombosis. However, there was a subgroup trend towards more bleeding with DOACs when initiated within 7 days of valve implantation. CONCLUSIONS: In the existing randomized literature on DOACs versus VKAs in the first 90 days after bioprosthetic valve implantation, there appears to be no difference with regard to thrombosis, bleeding or death. Interpretation of the data is limited by small numbers of events and wide confidence intervals. Future studies should focus on surgical valves and should include long-term follow-up to assess any potential impact of randomized therapy on valve durability.
引用
- Eikelboom R, Whitlock RP, Muzaffar R, et al. Direct oral anticoagulants versus vitamin K antagonists in the first 3 months after bioprosthetic valve replacement: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2023. PMID: 36971601. doi:10.1093/ejcts/ezad110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。